Shelton Capital Management trimmed its position in shares of Celgene Corporation (NASDAQ:CELG) by 4.1% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 102,073 shares of the biopharmaceutical company’s stock after selling 4,409 shares during the period. Celgene accounts for approximately 0.9% of Shelton Capital Management’s portfolio, making the stock its 18th largest holding. Shelton Capital Management’s holdings in Celgene were worth $13,256,000 at the end of the most recent reporting period.
Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Thompson Davis & CO. Inc. lifted its position in shares of Celgene by 5.9% during the second quarter. Thompson Davis & CO. Inc. now owns 773 shares of the biopharmaceutical company’s stock worth $100,000 after acquiring an additional 43 shares in the last quarter. Motco lifted its position in shares of Celgene by 19.3% during the second quarter. Motco now owns 981 shares of the biopharmaceutical company’s stock worth $127,000 after acquiring an additional 159 shares in the last quarter. Acropolis Investment Management LLC purchased a new stake in shares of Celgene during the second quarter worth $144,000. Rational Advisors LLC purchased a new stake in shares of Celgene during the second quarter worth $156,000. Finally, Oakworth Capital Inc. lifted its position in shares of Celgene by 11.7% during the second quarter. Oakworth Capital Inc. now owns 1,216 shares of the biopharmaceutical company’s stock worth $158,000 after acquiring an additional 127 shares in the last quarter. 80.17% of the stock is owned by institutional investors and hedge funds.
In other Celgene news, insider Terrie Curran sold 1,727 shares of the firm’s stock in a transaction dated Monday, September 25th. The stock was sold at an average price of $143.89, for a total transaction of $248,498.03. Following the sale, the insider now owns 3,925 shares in the company, valued at $564,768.25. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Gilla Kaplan sold 9,250 shares of the firm’s stock in a transaction dated Tuesday, September 12th. The shares were sold at an average price of $141.56, for a total value of $1,309,430.00. Following the sale, the director now owns 85,551 shares in the company, valued at approximately $12,110,599.56. The disclosure for this sale can be found here. Company insiders own 0.95% of the company’s stock.
Shares of Celgene Corporation (NASDAQ CELG) opened at $102.17 on Thursday. Celgene Corporation has a 12-month low of $94.55 and a 12-month high of $147.17. The company has a debt-to-equity ratio of 1.31, a quick ratio of 3.52 and a current ratio of 3.65. The firm has a market capitalization of $80,747.23, a PE ratio of 16.02, a price-to-earnings-growth ratio of 0.79 and a beta of 1.78.
Celgene (NASDAQ:CELG) last released its quarterly earnings results on Thursday, October 26th. The biopharmaceutical company reported $1.91 earnings per share for the quarter, beating the Zacks’ consensus estimate of $1.87 by $0.04. Celgene had a return on equity of 63.80% and a net margin of 27.36%. The business had revenue of $3.29 billion for the quarter, compared to the consensus estimate of $3.42 billion. During the same quarter last year, the business posted $1.58 earnings per share. The company’s revenue for the quarter was up 10.2% on a year-over-year basis. equities research analysts forecast that Celgene Corporation will post 6.67 EPS for the current fiscal year.
Several research firms have issued reports on CELG. William Blair restated an “outperform” rating on shares of Celgene in a research report on Friday, October 20th. Leerink Swann restated a “buy” rating and set a $156.00 target price on shares of Celgene in a research report on Friday, October 20th. Piper Jaffray Companies restated a “neutral” rating and set a $133.00 target price on shares of Celgene in a research report on Monday, October 23rd. Wells Fargo & Company downgraded Celgene from an “outperform” rating to a “market perform” rating in a research report on Thursday, October 26th. Finally, Vetr downgraded Celgene from a “buy” rating to a “hold” rating and set a $145.17 target price on the stock. in a research report on Wednesday, September 6th. One equities research analyst has rated the stock with a sell rating, eleven have issued a hold rating, nineteen have given a buy rating and two have issued a strong buy rating to the stock. The company presently has an average rating of “Buy” and an average target price of $139.57.
Celgene Company Profile
Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.
Receive News & Ratings for Celgene Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene Corporation and related companies with MarketBeat.com's FREE daily email newsletter.